secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056248
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025
--------------------------------------------------------------------------------

- Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.
- Cash, equivalents and marketable securities $239M after $161.8M public offering; runway extended into 2026.
- Positive Phase 2 dose exploration: nomlabofusp generally well-tolerated, dose-dependent frataxin increases in skin and buccal cells.
- First patient dosed in open-label extension (OLE) study of 25 mg daily; interim data on track for Q4 2024.
- BLA submission targeted second half 2025; FDA discussions underway for accelerated approval using frataxin as surrogate endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/0000950170-24-056248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/lrmr-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer